Home ›
Stock Message Boards ›
Stock Boards ›
Amarantus Bioscience Holdings (AMBS) Message Board

Amarantus Completes Enrollment of 72 Patient LP-00

Message Board

Public Reply |

Private Reply |

Keep |

Replies (1)

Post New Msg

Edit Msg () |

Previous

| Next

Post# of 30066

Posted On: 09/12/2014 10:30:54 AM

Posted By: brickbybrick

Amarantus Completes Enrollment of 72 Patient LP-002 Clinical Study for Alzheimer's Blood Diagnostic LymPro Test(R)

Quote:
SAN FRANCISCO and GENEVA, Sept. 12, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostic and therapeutic interventions for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, today announced that it has completed enrollment of the originally planned 72 patient LP-002 clinical study to assess the commercial feasibility of the company's flagship Alzheimer's blood diagnostic LymPro Test®. Amarantus previously released positive interim data from LP-002 on July 31, 2014 and expects to release data on the predictive value of individual LymPro markers (univariate) from the full cohort of 72 patients in the coming weeks.

"We look forward to releasing additional univariate data from the originally-planned 72 patient LP-002 clinical study in the near-term," said Gerald E. Commissiong, President & CEO of Amarantus. "We believe this data set will further position Amarantus to successfully target our initial Research Use Only (RUO) customer with LymPro as a stage-independent diagnostic, as discussed in our recent business update call."

Mr. Commissiong will be making a presentation today at the Aegis Capital 2014 Healthcare and Technology Conference that will be web cast live at 10:00 AM PT and available at http://wsw.com/webcast/aegis/ambs/.

The LP-002 trial was designed to replicate previously published peer-reviewed findings that demonstrated that LymPro was able to correctly distinguish Alzheimer's disease patients from healthy controls. LP-002 is evaluating LymPro's accuracy in both severe and moderate Alzheimer's disease. The subjects in the trial were recruited from four centers across the United States in order to mimic commercial shipping logistics for Laboratory Developed Tests ("LDT" under Clinical Laboratory Improvement Amendments ("CLIA" . Becton Dickinson's facility in La Jolla, CA is serving as the laboratory for LP-002. Amarantus is currently validating LymPro at Icon Central Laboratories ahead of commercial launch as an LDT.